Oxidative stress hypothesis in Alzheimer's disease

Free Radical Biology and Medicine

Volumn 23, Issue 1, 1997, Pages 134-147

  Markesbery, William R ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

4 Hydroxynonenal; Aluminum; Alzheimer's disease; Amyloid beta peptide; Antioxidants; Brain iron; Lipid peroxidation; Mercury; Oxidative stress; Protein and DNA oxidation

Indexed keywords

4 HYDROXYNONENAL; AMYLOID P COMPONENT; CYTOCHROME C OXIDASE; HEME OXYGENASE; MALONALDEHYDE; PEROXYNITRITE; POLYUNSATURATED FATTY ACID; SUPEROXIDE DISMUTASE;

ALZHEIMER DISEASE; ARTICLE; CELL DEATH; ENERGY METABOLISM; HUMAN; HUMAN CELL; HYPOTHESIS; LIPID PEROXIDATION; MOLECULAR DYNAMICS; NERVE CELL; NEUROFIBRILLARY TANGLE; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANTIOXIDANTS; CELL DEATH; DNA DAMAGE; FREE RADICALS; HUMANS; LIPID PEROXIDATION; NEUROFIBRILLARY TANGLES; NEURONS; OXIDATIVE STRESS;

EID: 0030915855     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(96)00629-6     Document Type: Article

References (155)

1. Alzheimer A. Uber eine eigenartige Erkrankung der Hirnride. Allg. Z. Psychiatr. 64:1907;146-148.
2. Evans D. A., Funkenstein H. H., Albert M. S., Scherr P. A., Cook N. R., Chown M. J., Hebert L. E., Hennekens C. H., Taylor J. O. Prevalence of Alzheimer's disease in a community population of older persons. JAMA. 262:1989;2551-2556.
3. Katzman R. The prevalence and malignancy of Alzheimer's disease: A major killer. Arch. Neurol. 33:1976;217-218.
4. National Institute on Aging. Progress report on Alzheimer's disease (NIH publications no. 95-3994) 1995, Washington DC: US Government Printing Office.
5. McKhann G. D., Drachman D. A., Folstein M. F., Katzman R., Price D., Stadlan E. M. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 34:1984;939-944.
6. Khachaturian Z. S. Diagnosis of Alzheimer's disease. Arch. Neurol. 42:1985;1097-1105.
7. Mirra S. S., Heyman A., McKeel D., Sumi S. M., Crain B. J., Brownlee L. M., Vogel F. S., Hughes J. P., Van Belle G., Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 41:1991;479-486.
8. Bartus R. T., Dean R. L., Beer B., Lippa A. S. The cholinergic hypothesis of geriatric memory dysfunction. Science. 217:1982;408-414.
9. Palmer A. M., Francis P. T., Benton J. S., Sims N. R., Mann D. M., Neary D., Snowden J. S., Bowen D. M. Presynaptic serotonergic dysfunction in patients with Alzheimer's disease. J. Neurochem. 48:1987;8-15.
10. Bowen D. M., Palmer A. M., Francis P. T., Proctor A. W., Lowe S. L. Classical neurotransmitters in Alzheimer's disease. Terry R. D. Aging and the brain. 1988;115-128 Raven Press, New York.
11. Davies P., Katzman R., Terry R. D. Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementia. Nature. 288:1980;279-280.
12. Bissette G., Reynolds G. P., Kilts C. A., Widerlov E., Nemeroff C. B. Corticotropin-releasing factor-like immunoreactivity in senile dementia of the Alzheimer type reduced cortical and striatal concentrations. JAMA. 254:1985;3067-3069.
13. Tanzi R. E., Kovacs D. M., Kim T. W., Moir R. D., Guenette S. Y., Wasco W. The presenilin genes and their role in early-onset familial Alzheimer's disease. Alz. Dis. Rev. 1:1996;90-98.
14. St. George-Hyslop P. H. The molecular genetics of Alzheimer disease. Terry R. D., Katzman R., Bick K. L. Alzheimer disease. 1993;345-352 Raven Press, New York.
15. Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., Roses A. D., Haines J. L., Pericak-Vance M. A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 261:1993;921-923.
16. Saunders A. M., Strittmatter W. J., Schmechel D., St. George-Hyslop P. H., Pericak-Vance M. A., Joo S. H., Gusella J. F., Crapper-MacLachlan D. R., Alberts M. J., Hulette C., Crain B., Goldgaber D., Roses A. D. Association of apolipoprotein E allele E4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 43:1993;1467-1472.
17. Corder E. H., Saunders A. M., Risch N. J., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Rimmler J. B., Locke P. A., Conneally P. M., Schmader K. E., Small G. W., Roses A. D., Haines J. L., Pericak-Vance M. A. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 7:1994;180-184.
18. Sherrington R., Rogaev E. I., Liang Y., Rogaeva E. A., Levesque G., Ikeda M., Chi H., Lin C., Li G., Holman K., Tsuda T., Mar L., Foncin J.-F., Bruni A. C., Montesi M. P., Sorbi S., Rainero I., Pinessi L., Nee L., Chumakov I., Pollen D., Brookes A., Sanseau P., Polinsky R. J., Wasco W., DaSilva H. A. R., Haines J. L., Pericak-Vance M. A., Tanzi R. E., Roses A. D., Fraser P. E., Rommens J. M., St. George-Hyslop P. H. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 375:1995;754-760.
19. Levy-Lahad E., Wasco W., Poorkaj P., Romano D. M., Oshima J., Pettingell W. H., Yu C. E., Jondro P. D., Schmidt S. D., Wang K., Crowley A. C., Fu Y. H., Guenette S. Y., Galas D., Nemens E., Wijsman E. M., Bird T. D., Schellenberg G. D., Tanzi R. E. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science. 269:1995;973-977.
20. Rogaev E. I., Sherrington R., Rogaeva E. A., Levesque G., Ikeda M., Liang Y., Chi H., Lin C., Holman K., Tsuda T., Mar L., Sorbi S., Nacmias B., Piacentini S., Amaducci L., Chumakov I., Cohen D., Lannfelt L., Fraser P. E., Rommens J. M., St George-Hyslop P. H. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature. 376:1995;775-778.
21. Henderson A. S. The epidemiology of Alzheimer's disease. Brit. Med. Bull. 42:1986;3-10.
22. Mortimer J. A., Hutton J. T. Epidemiology and etiology of Alzheimer's disease. Hutton J. T., Kenny A. D. Senile dementia of the Alzheimer's type. 1985;177-196 Alan R. Liss, Inc, New York.
23. Zhang M. Y., Katzman R., Salmon D., Jin H., Cai G. J., Wang Z. Y., Qu G. Y., Grant I., Yu E., Levy P. et al. The prevalence of dementia and Alzheimer's disease in Shanghai, China: impact of age, gender and education. Ann. Neurol. 27:1990;428-437.
24. Snowdon D. A., Kemper S. J., Mortimer J. A., Greiner L. H., Wekstein D. R., Markesbery W. R. Linguistic ability in early life and cognitive function and Alzheimer's disease in late life: findings from the Nun study. JAMA. 275:1996;528-532.
25. Markesbery W. R. Alzheimer's disease. Asbury A. K., McKhann G. M., McDonald W. I. Diseases of the nervous system: Clinical neurobiology. 1992;795-803 W. B. Saunders Co, Philadelphia.
26. Coyle J. T., Puttfarcken P. Oxidative stress, glutamate and neurodegenerative disorders. Science. 262:1993;689-695.
27. Olanow C. W. A radical hypothesis for neurodegeneration. Trends Neurosci. 16:1993;439-444.
28. Dexter D. T., Carter C. J., Agid F., Agid Y., Lees A. J., Jenner P., Marsden C. D. Lipid peroxidation as a cause of nigral cell death in Parkinson's disease. Lancet. 2:1986;639-640.
29. Dexter D. T., Carter C. J., Wells F. R., Javoy-Agid F., Agid Y., Lees A., Jenner P., Marsden C. D. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52:1989;381-389.
30. Rosen D. R., Siddique T., Patterson D., Figlewicz D. A., Sapp P., Hentati A., Donaldson D., Goto J., O'Regan J. P., Deng H.-X., Rahmani Z., Krizus A., McKenna-Yasek D., Cayabyab A., Gaston S. M., Berger R., Tanzi R. E., Halperin J. J., Herzfeldt B., Van den Bergh R., Hung W.-Y., Bird T., Deng G., Mulder D. W., Smyth C., Laing N. G., Soriano E., Pericak-Vance M. A., Haines J., Rouleau G. A., Gusella J. S., Horvitz H. R., Brown R. H. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 362:1993;59-62.
31. Gurney M. E., Pu H., Chiu A. Y., Dal Canto M. C., Polchow C. Y., Alexander D. D., Caliendo J., Hentati A., Kwon Y. W., Deng H., Chen W., Zhai P., Sufit R. L., Siddique T. Motor neuron degeneration in mice that express a human Cu, Zn, superoxide dismutase mutation. Science. 264:1994;1772-1775.
32. Wong P., Pardo C. A., Borchelt D. R., Lee M. K., Copeland N. G., Jenkins N. A., Sisodia S. S., Cleveland D. W., Price D. L. An adverse property of a familial ALS-linked SOD-1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron. 14:1995;1105-1116.
33. Wiedau-Pazos M., Goto J. J., Rabizadeh S., Gralla E. B., Roe J. A., Lee M. K., Valentine J. S., Bredesen D. E. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. Science. 271:1996;515-518.
34. Ince P. G., Shaw P. J., Candy J. M., Mantle D., Tandon L., Ehmann W. D., Markesbery W. R. Iron, selenium, glutathione peroxidase activity are elevated in sporadic motor neuron disease. Neurosci. Lett. 182:1994;87-90.
35. Markesbery W. R., Ehmann W. D., Candy J. M., Ince P. G., Shaw P. J., Tandon L., Deibel M. A. Neutron activation analysis of trace elements in motor neuron disease spinal cord. Neurodegeneration. 4:1995;383-390.
36. Markesbery W. R., Ehmann W. D. Brain trace elements in Alzheimer disease. Terry R. D., Katzman R., Bick K. L. Alzheimer disease. 1993;353-367 Raven Press, New York.
37. Halliwell B., Gutteridge J. M. C. Free radicals in biology and medicine. ed 2:1989;Clarendon Press, Oxford.
38. Goodman L. Alzheimer's disease: A clinico-pathologic analysis of twenty-three cases with a theory on pathogenesis. J. Nerv. Ment. Dis. 117:1953;97-130.
39. Ehmann W. D., Markesbery W. R., Alauddin M., Hossain T. I. M., Brubaker E. H. Brain trace elements in Alzheimer's disease. Neurotoxicology. 7:1986;197-206.
40. Thompson C. M., Markesbery W. R., Ehmann W. D., Mao Y.-X., Vance D. E. Regional brain trace-element studies in Alzheimer's disease. Neurotoxicology. 9:1988;1-8.
41. Samudralwar D. L., DiPrete C. C., Ni B. F., Ehmann W. D., Markesbery W. R. Elemental imbalances in the olfactory pathway in Alzheimer's disease. J. Neurol. Sci. 130:1995;139-145.
42. Good P. F., Perl D. P., Bierer L. M., Schmeidler J. Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: A laser microprobe (LAMMA) study. Ann. Neurol. 31:1992;286-292.
43. Fleming J., Joshi J. G. Ferritin: Isolation of aluminum-ferritin complex from brain. Proc. Natl. Acad. Sci. USA. 84:1987;7866-7870.
44. Switzer R. C., Martin T. L., Campbell S. K., Parker J. C., Caldwell E. D. Iron and ferritin in the neuritic plaques of Alzheimer's disease. Soc. Neurosci. Abstract. 100 abstr:1986.
45. Loeffler D. A., Connor J. R., Juneau P. L., Snyder B. S., Kanaley L., DeMaggio A. J., Nguyen H., Brickman C. M., LeWitt P. A. Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J. Neurochem. 65:1995;710-716.
46. Grundke-Iqbal I., Fleming J., Tung Y.-C., Lassmann H., Iqbal K., Joshi J. G. Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia. Acta Neuropathol. 81:1990;105-110.
47. Robinson S. R., Noone D. F., Kril J., Halliday G. M. Most amyloid plaques contain ferritin-rich cells. Alz. Res. 1:1995;191-196.
48. Kennard M. L., Feldman H., Yamada T., Jefferies W. A. Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease. Nature Med. 2:1996;1230-1235.
49. Jefferies W. A., Food M. R., Gabathuler R., Rothenberger S., Yamada T., Yasuhara O., McGeer P. L. Reactive microglia specifically associated with amyloid plaques in Alzheimer's disease brain tissue express melanotransferrin. Brain Res. 712:1996;122-126.
50. Xu N., Majidi V., Markesbery W. R., Ehmann W. D. Brain aluminum in Alzhemier's disease using improved GFAAS method. Neurotoxicology. 13:1992;735-744.
51. Evans P. H., Peterhan E., Bürge T., Klinowski J. Aluminosilicate-induced free radical generation by murine brain glial cells in vitro: Potential significance in the aetiopathogenesis of Alzheimer's dementia. Dementia. 3:1992;1-6.
52. Fraga C. G., Oteiza P. I., Golub M. S., Gershwin M. E., Keen C. L. Effect of aluminum on brain lipid peroxidation. Toxicol. Lett. 51:1990;213-219.
53. Gutteridge J. M. C., Quinlan G. J., Clark I., Halliwell B. Aluminum salts accelaerate peroxidation of membrane lipids stimulated by iron salts. Biochem. Biophys. Acta. 835:1985;441-447.
54. Oteiza P. I. A mechanism for the stimulatory effect of aluminum on iron-induced lipid peroxidation. Arch. Biochem. Biophys. 308:1994;374-379.
55. Stacey N. H., Kappus H. Cellular toxicity and lipid peroxidation in response to mercury. Toxiocol. App. Pharmacol. 63:1982;29-35.
56. Deibel M. A., Ehmann W. D., Markesbery W. R. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. J. Neurol. Sci. in press. 143:1996;137-142.
57. Connor J. R., Tucker P., Johnson M., Snyder B. Ceruloplasmin levels in the human superior temporal gyrus in aging and Alzheimer's disease. Neurosci. Lett. 159:1993;88-90.
58. Samokyszyn V. M., Reif D. W., Miller D. M., Aust S. D. Effects of ceruloplasmin on superoxide dependent iron release from ferritin and lipid peroxidation. Free Radic. Res. Comms. 12-13:1991;153-159.
59. Multhaup G., Schlicksupp A., Hesse L., Beher D., Ruppert T., Masters C. L., Beyreuther K. The amyloid precursor protein of Alzheimer's disease in the reduction of Copper (II) to Copper (I). Science. 271:1996;1406-1409.
60. Smith C. D., Carney J. M., Starke-Reed P. E., Oliver C. N., Stadtman E. R., Floyd R. A., Markesbery W. R. Excess brain protein oxidation and enzyme dysfunction in normal aging and Alzheimer disease. Proc. Natl. Acad. Sci. USA. 88:1991;10540-10543.
61. Hensley K., Hall N., Subramaniam R., Cole P., Harris M., Aksenov M., Aksenova M., Gabbita S. P., Wu J. F., Carney J. M., Lovell M., Markesbery W. R., Butterfield D. A. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J. Neurochem. 65:1995;2146-2156.
62. Hensley K., Carney J. M., Hall N., Shaus W., Butterfield D. A. Electron paramagnetic resonance investigations of free radical induced alterations in neocortical synaptosomal membrane protein infrastructure. Free Radic. Biol. Med. 17:1994;321-331.
63. Mecocci P., MacGarvey U., Kaufman A. E., Koontz D., Shoffner J. M., Wallace D. C., Beal M. F. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann. Neurol. 34:1993;609-616.
64. Mecocci P., MacGarvey U., Beal M. F. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol. 36:1994;747-751.
65. Lovell M. A., Ehmann W. D., Butler S. M., Markesbery W. R. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology. 45:1995;1594-1601.
66. Subbarao K. V., Richardson J. S., Ang L. C. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J. Neurochem. 55:1990;342-345.
67. Balazs L., Leon M. Evidence of an oxidative challenge in the Alzheimer's brain. Neurochem. Res. 19:1994;1131-1137.
68. Hajimohammadreza I., Brammer M. Brain membrane fluidity and lipid peroxidation in Alzheimer's disease. Neurosci. Lett. 112:1990;333-337.
69. Palmer A. M., Burns M. A. Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease. Brain Res. 645:1994;338-342.
70. Cohen G., Werner P. Free radicals, oxidative stress and neurodegeneration. Calne D. B. Neurodegenerative diseases. 1994;139-161 WB Saunders Co, Philadelphia.
71. Busciglio J., Yankner B. A. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature. 378:1995;776-779.
72. Hazel J. R., Williams E. E. The role of alterations in membrane lipid composition in enabling physiological adaptation of organisms to their physical environment. Prog. Lipid. Res. 29:1990;167-227.
73. Halliwell B. Oxidants and the central nervous system: some fundamental questions. Is oxidant damage relevant to Parkinson's disease, Alzheimer's disease, traumatic injury or stroke? Acta Neurol. Scand. 126:1989;23-33.
74. 31P nuclear magnetic resonance study of the brain in Alzheimer's disease. J Neuropathol. Exp. Neurol. 47:1988;235-248.
75. Miatto O., Gonzalez R. G., Buonanno F., Growdon J. H. In vitro 31p NMR spectroscopy detects altered phospholipid metabolism in Alzheimer's disease. Can. J. Neurol. Sci. 13:1986;535-539.
76. Nitsch R. M., Blusztajn J. K., Pittas A. G., Slack B. E., Growdon J. H., Wurtman R. J. Evidence for a membrane defect in Alzheimer disease brain. Proc. Natl. Acad. Sci. USA. 89:1992;1671-1675.
77. Prasad, M. R.; Lovell, M. A.; Yatkin, M.; Dhillon, H.; Markesbery, W. R. Regional membrane phospholipid alterations in Alzheimer's disease. Brain Research (submitted).
78. Svennerholm L., Gottfries C. G. Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset (type I) and demyelination in late-onset form (type II). J. Neurochem. 62:1994;1039-1047.
79. Esterbauer H., Schaur R. J., Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehyes. Free Radic. Biol. Med. 11:1991;81-128.
80. Lovell, M. A.; Ehmann, W. D.; Markesbery, W. R. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease.Neurobiology of Aging (submitted).
81. Mark R. J., Lovell M. A., Markesbery W. R., Uchida K., Mattson M. P. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid β -peptide. Journal of Neurochemistry. 68:1997;255-264.
82. +-ATPase. Free Radic. Biol. Med. 20:1996;215-223.
83. Montine T. J., Amarnath V., Martin M. E., Strittmatter W. J., Graham D. G. E-4-hydroxy-2-nonenal is cytotoxic and cross-links cytoskeletal proteins in P19 neuroglial cultures. Am. J. Pathol. 148:1996;89-93.
84. Montine T. J., Huang D. Y., Valentine W. M., Amarnath V., Saunders A., Weisgraber K. H., Graham D. G., Strittmatter W. J. Crosslinking of apolipoprotein E by products of lipid peroxidation. J. Neuropathol. Exp. Neurol. 55:1996;202-210.
85. Kish S. J., Morito C. L., Hornykiewicz O. Brain glutathione peroxidase in neurodegenerative disorders. Neurochem. Pathol. 4:1986;23-28.
86. Gsell W., Conrad R., Hickethier M., Sofic E., Frölich L., Wichart I., Jellinger K., Moll G., Ransmayr G., Beckmann H., Riederer P. Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type. J. Neurochem. 64:1995;1216-1223.
87. Kato K., Kurobe N., Suzuki R., Morishita R., Asano T., Sato T., Inagaki T. Concentrations of several proteins characteristic of nervous tissue in cerebral cortex of patients with Alzheimer's disease. J. Mol. Neurosci. 3:1991;95-99.
88. Richardson J. S. Free radicals in the genesis of Alzheimer's disease. Ann. NY Acad. Sci. 695:1993;73-76.
89. Marklund S. L., Adolfsson R., Gottfries C. G., Winblad B. Superoxide dismutase isoenzymes in normal brains and in brains from patients with dementia of Alzheimer type. J. Neurol. Sci. 67:1985;319-325.
90. Monnier V. M., Cerami A. Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. Science. 211:1981;491-493.
91. Smith M. A., Sayre L. M., Monnier V. M., Perry G. Radical AGEing in Alzheimer's disease. Trends Neurosci. 18:1995;172-176.
92. Sell D. R., Monnier V. M. Structure elucidation of a senescence cross-link from human extracellular matrix: implication of pentoses in the aging process. J. Biol. Chem. 264:1989;21597-21602.
93. Hunt J. V., Wolff S. P. Oxidative glycation and free radical production: a causal mechanism of diabetic complications. Free Radic. Res. Commun. 12-13 Pt. 1:1991;115-123.
94. Vitek M. P., Bhattacharya K., Glendening J. M., Stopa E., Vlassara H., Bucala R., Manogue K., Cerami A. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Natl. Acad. Sci. USA. 91:1994;4766-4770.
95. Smith M. A., Taneda S., Richey P. L., Miyata S., Yan S.-D., Stern D., Sayre L. M., Monnier V. M., Perry G. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc. Natl. Acad. Sci. USA. 91:1994;5710-5714.
96. Yan S. D., Chen X., Schmidt A-M., Brett J., Godman G., Zou Y. S., Scott C. W., Caputo C., Frappier T., Smith M. A., Perry G., Yen S. H., Stern D. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc. Natl. Acad. Sci. USA. 91:1994;7787-7791.
97. Smith M. A., Perry G., Richey P. L., Sayre L. M., Anderson V. E., Beal M. F., Kowall N. Oxidative damage in Alzheimer's. Nature. 382:1996;120-121.
98. Carpenter A. F., Carpenter P. W., Markesbery W. R. Morphometric analyses of microglia in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 52:1993;601-608.
99. Dickson D. W., Farlo J., Davies P., Crystal H., Field P., Yen S. H. Alzheimer's disease: a double-labeling immunohistochemical study of senile plaques. Am. J. Pathol. 132:1988;86-101.
100. Colton C. A., Snell J., Chernyshev O., Gilbert D. L. Induction of superoxide anion and nitric oxide production in cultural microglia. Ann. NY Acad. Sci. 78:1994;54-63.
101. Goodwin J. L., Uemura E., Cunnick J. E. Microglia release of nitric oxide by the synergistic action of β -amyloid and IFN-g. Brain Res. 692:1995;207-214.
102. Good P. F., Werner P., Hsu A., Olanow C. W., Perl D. P. Evidence for neuronal oxidative damage in Alzheimer's disease. Am. J. Pathol. 149:1996;21-28.
103. Pappolla M. A., Omar R. A., Kim K. S., Robakis N. K. Immunohistochemical evidence of antioxidant stress in Alzheimer's disease. Am. J. Pathol. 140:1992;621-628.
104. Smith M. A., Kutty R. K., Richey P. L., Yan S. D., Stern D., Chader G. J., Wiggert B., Petersen R. B., Perry G. Heme-oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am. J. Pathol. 145:1994;42-47.
105. Schipper H. M., Cissé S., Stopa E. G. Expression of heme oxygenase-1 in the senescent and Alzheimer-disease brain. Ann. Neurol. 37:1995;758-768.
106. Premkumar D. R. D., Smith M. A., Richey P. L., Petersen R. B., Castellani R., Kutty R. K., Wiggert B., Perry G., Kalaria R. N. Induction of heme oxygenase-1 mRNA and protein in neocortex and cerebral vessels in Alzheimer's disease. J. Neurochem. 65:1995;1399-1402.
107. 2+ concentration, and neurotoxicity and increase antioxidant enzyme activities in hippocampal neurons. J. Neurochem. 65:1995;1740-1751.
108. Behl C., Davis J. B., Lesley R., Schubert D. Hydrogen peroxide mediates amyloid β protein toxicity. Cell. 77:1994;817-827.
109. Butterfield D. A., Hensley K., Harris M., Mattson M. P., Carney J. β -amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-specific fashion: implications to Alzheimer's disease. Biochem. Biophys. Res. Commun. 200:1994;710-715.
110. Dyrks T., Dyrks E., Hartmann R., Masters C., Beyreuther K. Amyloidogenicity of βA4 and βA4 -bearing amyloid protein precursor fragments by metal-catalyzed oxidation. J. Biol. Chem. 267:1992;18210-18217.
111. Hensley K., Carney J. M., Mattson M. P., Aksenova M., Harris M., Wu J. F., Floyd R. A., Butterfield D. A. A model for β -amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 91:1994;3270-3274.
112. Harris M. E., Hensley K., Butterfield D. A., Leedle R. A., Carney J. M. Direct evidence of oxidative injury produced by the Alzheimer's β -amyloid peptide (1-40) in cultured hippocampal neurons. Exp. Neurol. 131:1995;193-202.
113. Goodman Y., Mattson M. P. Secreted forms of β -amyloid precursor protein protect hippocampal neurons against amyloid β -peptide-induced oxidative injury. Exp. Neurol. 128:1994;1-12.
114. Thomas T., Thomas G., McLendon C., Sutton T., Mullan M. β -amyloid-mediated vasoactivity and vascular endothelial damage. Nature. 380:1996;168-171.
115. Beal M. F. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38:1995;357-366.
116. Hoyer S. Brain oxidative energy and related metabolism, neuronal stress and Alzheimer's disease: A speculative synthesis. J. Geriatr. Psychiatry Neurol. 6:1993;3-13.
117. Beal M. F. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol. 31:1992;119-130.
118. Wallace D. C. Diseases of the mitochondrial DNA. Ann. Rev. Biochem. 61:1992;1175-1212.
119. Bowling A. C., Mutisya E. M., Walker L. C., Price D. L., Cork L. C., Beal M. F. Age-dependent impairment of mitochondrial function in primate brain. J. Neurochem. 60:1993;1964-1967.
120. Benzi G., Pastoris O., Marzatico F., Villa R. F., Dagani F., Curti D. The mitochondrial electron transfer alteration as a factor involved in the brain aging. Neurobiol. Aging. 13:1992;361-368.
121. Curti D., Giangaré M. C., Redolfi M. E., Fugaccia I., Benzi G. Age-related modifications of cytochrome c oxidase activity in discrete brain regions. Mech. Ageing Dev. 55:1990;171-180.
122. Parker W. D., Parks J. K., Filley C. M., Kleinschmidt-DeMasters B. K. Electron transport chain defects in Alzheimer's disease brain. Neurology. 44:1994;1090-1096.
123. Kish S. J., Bergeron C., Rajput A., Dozie S., Mastrogiacomo F., Chang L. J., Wilson J. M., Distefano L. M., Nobrega J. N. Brain cytochrome oxidase in Alzheimer's disease. J. Neurochem. 59:1992;776-779.
124. Mutisya E. M., Bowling A. C., Beal M. F. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J. Neurochem. 63:1994;2179-2184.
125. Chagnon P., Bétard C., Robitaille Y., Cholette A., Gauvreau D. Distribution of brain cytochrome oxidase activity in various neurodegenerative diseases. NeuroReport. 6:1995;711-715.
126. Simonian N. A., Hyman B. T. Functional alterations in Alzheimer's disease: diminution of cytochrome oxidase in the hippocampal formation. J. Neuropathol. Exp. Neurol. 52:1993;580-585.
127. Simonian N. A., Hyman B. T. Functional alterations in Alzheimer's disease: selective loss of mitochondrial-encoded cytochrome oxidase mRNA in the hippocampal formation. J. Neuropathol. Exp. Neurol. 53:1994;508-512.
128. Chandrasekaran K., Giordano T., Brady D. R., Stoll J., Martin L. J., Rapoport S. I. Impairment in mitochondrial cytochrome oxidase gene expression in Alzheimer's disease. Mol. Brain Res. 24:1994;336-340.
129. Parker W. D., Parks J. K. Cytochrome c oxidase in Alzheimer's disease brain: purification and characterization. Neurology. 45:1995;482-486.
130. Partridge R. S., Munroe S. M., Parks J. K., Johnson K., Parker W. D., Eaton G. R., Eaton S. S. Spin trapping of azidyl and hydroxyl radicals in azide-inhibited rat brain submitochondrial particles. Arch. Biochem. Biophys. 310:1994;210-217.
131. Lipton S. A., Rosenberg P. A. Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. 330:1994;613-622.
132. Whetsell W. O. Current concepts of excitotoxicity. J. Neuropathol. Exp. Neurol. 55:1996;1-13.
133. Novelli A., Reilly J. A., Lysko P. G., Henneberry R. C. Glutamate become neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res. 451:1988;205-212.
134. Verity M. A. Mechanisms of phospholipase A2 activation and neuronal injury. Ann. NY Acad. Sci. 679:1993;110-120.
135. McCord J. Oxygen-derived free radicals in postischemic tissue injury. N. Engl. J. Med. 312:1985;159-163.
136. Saito K.-I., Elce J. S., Hamos J. E., Nixon R. A. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer's disease: a potential molecular basis for neuronal degeneration. Proc. Natl. Acad. Sci. USA. 90:1993;2628-2632.
137. Lipton S. A., Choi Y. B., Pan Z.-H., Lei S. Z., Chen H.-S. U., Sucher N. J., Loscalzo J., Singel D. J., Stamler J. S. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature. 364:1993;626-632.
138. Yanker B. A., Duffy L. K., Kirschner D. A. Neurotrophic and neurotoxic effects of amyloid beta protein: Reversal by tachykinin neuropeptides. Science. 250:1990;279-282.
139. Koh J.-Y., Yang L. L., Cotman C. W. β -amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res. 533:1990;315-320.
140. Mattson M. P., Cheng B., Davis D., Bryant K., Lieberburg I., Rydel R. E. β -amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12:1992;376-389.
141. Copani A., Koh J.-Y., Cotman C. W. β -amyloid increases neuronal susceptibility to injury by glucose deprivation. NeuroReport. 2:1991;763-765.
142. Goodman Y., Steiner M. R., Steiner S. M., Mattson M. P. Nordihydroguaiaretic acid protects hippocampal neurons against amyloid β -peptide toxicity, and attenuates free radical and calcium accumulation. Brain Res. 654:1994;171-176.
143. Dykens J. A., Stern A., Trenkner E. Mechanism of kainate toxicity to cerebellar neurons in vitro is analogous to reperfusion tissue injury. J. Neurochem. 49:1987;1222-1228.
144. Kelly J. F., Furukawa K., Barger S. W., Rengen M. R., Mark R. J., Blanc E. M., Roth G. S., Mattson M. P. Amyloid β -peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons. Proc. Natl. Acad. Sci. 93:1996;6753-6758.
145. Mark R. J., Blanc E. M., Mattson M. P. Amyloid β -peptide and oxidative cellular injury in Alzheimer's disease. Mol. Neurobiol. 12:1996;211-224.
146. Mattson M. P. Calcium and free radicals: Mediators of neurotrophic factor and excitatory transmitter-regulated developmental plasticity and cell death. Pers. Dev. Neurobiol. 3:1996;79-91.
147. Mattson M. P., Cheng B., Smith-Swintosky V. L. Growth factor-mediated protection from excitotoxicity and disturbances in calcium and free radical metabolism. Semin. Neurosci. 5:1993;295-307.
148. Jackson G. R., Apffel L., Werrback-Perez K., Perez-Polo J. R. Role of nerve growth factor in oxidant-antioxidant balance and neuronal injury stimulation of hydrogen peroxide resistance. J. Neurosci. Res. 25:1990;360-368.
149. Pan Z., Perez-Polo R. Role of nerve growth factor in oxidant homeostasis: glutathione metabolism. J. Neurochem. 61:1993;1713-1721.
150. Cheng B., Mattson M. P. PDGFs protect hippocampal neurons against energy deprevation and oxidative injury: evidence for induction of antioxidant pathways. J. Neurosci. 15:1995;7095-7104.
151. Troy C. M., Shelanski M. L. Down-regulation of copper/zinc superoxide dismutase (SOD1) causes apoptotic death in PC12 neuronal cells. Proc. Natl. Acad. Sci. USA. 91:1994;6384-6387.
152. Troy C. M., Derossi D., Prochiantz A., Greene L. A., Shelanski M. L. Down-regulation of Cu/Zn superoxide dismutase leads to cell death via the nitric oxide-peroxynitrite pathway. J. Neurosci. 16:1996;253-261.
153. Breitner J. C. S., Welsh K. A., Helms M. J., Gaskell P. C., Gau B. A., Roses A. D., Pericak-Vance M. A., Saunders A. M. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol. Aging. 16:1995;523-530.
154. Rich J. B., Rasmusson D. X., Folstein M. F., Carson K. A., Kawas C., Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology. 45:1995;51-55.
155. Crapper McLachlan D. R., Dalton A. J., Kruck T. P. A., Bell M. Y., Smith W. L., Kalow W., Andrews D. F. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet. 337:1991;1304-1308.